Implications of biological prognostic factors for the treatment of nonseminomatous testicular tumours in clinical stage I the present status;Einfluß biologischer prognosefaktoren auf die therapie nichtseminomatöser hodentumoren im klinischen Stadium I - Eine standortbestimmung

Urologe - Ausgabe A

Volumn 35, Issue 1, 1996, Pages 35-45

  Kuczyk, M A ^a   Bokemeyer, C ^a   Serth, J ^a   Machtens, S ^a   Hofner K ^a   Jonas, U ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Biological prognostic parameters p 53 tumour suppressor gene; Clinical stage i; Histological prognostic parameters; Nonseminomatous germ cell tumours

Indexed keywords

PROTEIN P53; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; CANCER STAGING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW; SURVIVAL RATE; TESTIS TUMOR; HISTOLOGY; TESTIS NONSEMINOMA CANCER;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; SURVIVAL RATE; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030068805     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Allhoff EP, Liedke S, de Riese W, Stief CG, Tanke HJ, Schneider B, Kramer AEJL, Jonas U (1991) Assessment of individual prognosis for patients with NSGCT/CS I. J Urol 145: 367 A
2. Albers P, Ulbright TM, Albers J, Miller GA. Foster RS, Donohue JP (1995) New prognostic parameters to predict pathological stage A nonseminomatous testicular germ cell tumors (NSGCT). J Urol 153: 244 A
3. Atkin NB, Baker MC (1982) Specific chromosome change, i(12p), in testicular tumours. Lancet 2: 1349
4. Babaian RJ, Bracken RB, Johnson DE (1981) Complications of transabdominal retroperitoneal lymphadenectomy. Urology 17: 126-128
5. Bokemeyer C, Schmoll H-J, Kuczyk MA, Beyer J, Siegert G (1995) Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Natl Cancer Inst 87: 58-60
6. Bosl GJ, Dimitrovsky E, Reuter VE, Samaniego F, Rodriguez E, Geller NL, Chaganti RS: Isochromosome of the short arm of chromosome 12 (1989) Clinically useful markers for male germ cell tumors. J Natl Cancer Inst 81: 1874
7. Bürger RA, Braun MH, Witzsch U, Potratz D, Stöckle M, Hohenfellner R (1993) Automated DNA-image analysis in testicular cancer: value of 5c exceeding rate as prognostic factor. J Urol 149: 390 A
8. Chevreau C, de Forni M, Soulie M, Mihura J, Plante P (1991) Is adjuvant chemotherapy a beneficial treatment in stage I high risk nonseminomatous testicular germ cell tumors? ECCO 6, EJC [Suppl 2]: 651 A
9. Costello AJ, Mortensen PH, Stillwell RG (1989) Prognostic indicators for failure of surveillance management of stage I nonseminomatous germ cell tumors. Aust NZ J Surg 59: 119-122
10. Cullen M (1991) Management of stage I non-seminoma: surveillance and chemotherapy. In: Horwich A (ed) Testicular cancer. Investigation and management. Chapman & Hall, London New York, pp 149-166
11. Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Horwich AH, Kayer SB, Harland SJ, Williams MV, Jakes R (1995) Ahort course adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumours of the testis (NSGCT): an MRC (UK) study report. Proc Am Soc Clin Oncol 14: 244 A
12. De Riese WTW, Walker EB, De Riese C, Jones JA, Foster RS, Donohue JP, Messemer J (1993) Predictive value of proliferative parameters measured by flow cytometry in early stage non- seminomatous germ cell tumors (NSGCT). J Urol 149: 962 A
13. Donohue JP (1987) Controversies in testis cancer management. In: de Kernion J, Paulson D (eds) Genitourinary cancer management. Lea & Febiger. Philadelphia pp 161-186
14. Donohue JP (1990) Nerve-sparing retroperitoneal lymphadenectomy. In: Jäger N, Hartlapp JH (Hrsg) Aktueller Stand der Diagnostik und Therapie von Hodentumoren. Beitr. Onkol. Bd 40. Karger, Basel, S 124-132
15. Donohue JP (1987) Management of low clinical stage testis cancer (editorial comment). Urol Clin North Am 14: 729-730
16. Donohue JP, Einhorn LH, Perez JM (1978) Improved management of non-seminomatous testis tumors. Cancer 42: 2903-2908
17. Donohue JP, Rowland RG (1981) Complications of retroperitoneal lymph node dissection. J Urol 125: 338-340
18. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R (1993) Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965-1989): modifications of technique and impact on ejaculation. J Urol 149: 237-243
19. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R (1993) Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer: review of the Indiana University experience 1965-1989. Br J Urol 71: 326-335
20. Dunphy CH, Ayala AG, Swanson DA, Ro JY, Logothetis C (1988) Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. Cancer 62: 1202-1206
21. Fernandez EB, Sesterhenn IA, McCarthy WF, Mostofi FK, Moul JW (1994) Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. J Urol 152: 1133-1138
22. Fossa SD, Kreuser ED (1990) Fertility in patients with testicular cancer. In: Jäger N, Hartlapp JH (Hrsg) Aktueller Stand der Diagnostik und Therapie von Hodentumoren. Beitr. Onkol. Bd 40. Karger. Basel, S 124-132
23. Fossa SD, Nesland JM, Waehre H, Amellem O, Pattersen EO (1991) DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I. Cancer 67: 1984
24. Fossa SD, Ous S, Abyholm T et al (1985) Post-treatment fertility in patients with testicular cancer. II. Influence of cis platin - based combined chemotherapy and of retroperitoneal surgery on hormone and sperm cell production. Br J Urol 57: 210-214
25. Fossa S.D., Ous S, Stenwig AE, Lien HH, Aas N, Kaalhus O (1990) Distribu- tion of retroperitoneal lymph node metastases in patients with non-seminomatous testicular cancer in clinical stage I. Eur Urol 17: 107-112
26. Fraley EE, Narayan P, Vogelzang NJ et al (1985) Surgical treatment of patients with stage I and II non-seminomatous testicular cancer. J Urol 134: 70-73
27. Freedman LS, Parkinson MC, Jonas WG, Oliver RTD, Peckham MJ, Read G, Newlands ES, Williams CJ (1987) Histopathology in the prediction of relapse of patients with with stage I testicular teratoma treated by orchiectomy alone. Lancet 2: 294-298
28. Fung CY, Kalish LA, Brodsky GL, Richie JP, Garnick MB (1988) Stage I nonseminomatous germ cell testicular tumor: prediction of metastatic potential by primary histopathology. J Clin Oncol 6: 1467-1473
29. Gazdar A (1992) Molecular markers for the diagnosis and prognosis of lung cancer. Cancer 69: 1592-1599
30. Gibas Z, Prout GR, Sandberg AA (1984) Malignant treatoma of the testis with an isochromosome No. 12. i(12p), as the sole structural cytogenetic abnormality. J Urol 139: 762
31. Gimmi C, Sonntag R, Brunner K (1990) Adjuvant treatment of high risk (HR) clinical stage I testicular carcinoma (TC) with cisplatin (C), bleomycin (B) and vinblastine (V) or etoposide (E). Proc Am Soc Clin Oncol 8: 140
32. Gressler V, Levine L, Vogelzang N (1990) A third option in the management of patients with clinical stage 1, non-seminomatous germ cell tumor? J Clin Oncol 8: 4-8
33. Hoskin P, Dilly S, Easton D, Heroic A, Hendry W, Peckham MJ (1986) Prognostic factors in stage I nonseminomatous germ cell testicular tumors managed by orchiectomy and surveillance. Implications for adjuvant chemotherapy. J Clin Oncol 4: 1031-1036
34. Jacobson GK, Rorth M, Osterlind K, von der Maase H, Jacobson A, Madsen EL, Pedersen M, Schultz H, Danish Testicular Cancer Study Group (1990) Histopathological features in stage I non-seminomatous testicular germ cell tumors correlated to relapse. APMIS 98: 377-382
35. Jewett MAS, Kong Y-SP, Golberg SD, Sturgeon JFG, Thomas GM, Alison RE, Gospodarowicz MK (1988) Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 139: 1220-1224
36. Jewett MAS, Torbey C (1988) Nerve sparing techniques in retroperitoneal lymphadenectomy in patients with low-stage testicular cancer. Semin Urol 6: 233-237
37. Kleinschmidt K, Weißbach L (1990) Stellenwert der Kryospermakonservie- rung zur Fertilitätsbehandlung bei Hodentumorpatienten. In: Jäger N, Hartlapp JH (Hrsg) Aktueller Stand der Diagnostik und Therapie von Hodentumoren. Beitr. Onko., Bd 40. Karger, Basel, S 133-142
38. Klepp O, Olsson AM, Henrikson H, Aas N, Dahl O, Stenwig AE, Persson BE, Cavallin-Stahl E, Fossa SD, Wahlquist L for the Swedish-Norwegian Testicular Cancer Group (1990) Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. J Clin Oncol 8: 509-518
39. Kuczyk MA, Serth J, Bokemeyer C, Hervatin C, Oelke M, Oelert F, Höfner K, Jonas U (1995) Wertigkeit von Proliferationsstatus (PCNA) und p 53 - Immunnistochemie als Prognosefaktor fur den klinischen Verlauf superfizieller Harnblasenkarzinome. Urologe [A] 34: 146-152
40. Kuczyk MA, Serth J, Bokemeyer C, Allhoff EP, Jonassen J, Kuczyk S, Jonas U (1994) Overexpression of the p53 oncoprotein in carcinoma in situ of the testis. Pathol Res Pract 190: 993-998
41. Kuczyk MA, Serth J, Bokemeyer C, Pietsch T, Höfner K, Jonas U (1995) Stem cell factor und sein Rezeptor c-kit. Bedeutung für die Keimzellmaturation und die Pathogenese testikulärer Keimzelltumoren. Akt Urol (im Druck)
42. Lange PH, Change WY, Fraley EE (1987) Fertility issues in the therapy of nonseminomatous testicular tumors. Urol Clin North Am 14: 731-747
43. Lewis DJ, Sesterhenn IA, McCarthy WF, Moul JW (1994) Immunohistochemical expression of p 53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease. J Urol 152: 418-423
44. Madej G, Pawinski A (1991) Risk-related adjuvant chemotherapy for stage I non seminoma of the testis. In: New trends in diagnosis and treatment of testicular tumours: Third international symposium on advances in urologic oncology. San Remo, p 51
45. McLeod DG, Weiss RB, Stablein DM, Muggia FM, Paulson DF, Ellis JH, Spaulding JT, Donohue JP (1991) Staging relationships and outcome in early stage testicular cancer: A report from the Testicular Cancer Intergroup Study. J Urol 145: 1178-1183
46. Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA (1994) Percentage of embryonal carcinoma and vascular invasion predict pathologic stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 54: 1-3
47. Moul JW, Foley JP, Hitchcock CL, McCarthy WF, Sesterhenn IA, Becker RL, Griffin JL (1993) Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. J Urol 150: 879-883
48. Moul JW, Robertson JE, George SL et al (1989) Complications of therapy for testicular cancer. J Urol 142: 1491-1496
49. Moul JW, Theune SM, Chang EH (1992) Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization. Genes. Chromosomes Cancer 5: 109-118
50. Murty VVVS, Houldsworth J, Baldwin S et al (1992) Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors. Proc Natl Acad Sci USA 89: 11006-11011
51. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hosteller R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p 53 gene occur in diverse human tumor types. Nature 342: 705-708
52. Oliver RTD, Raja MA, Ong J (1992) Pilot study to evaluate impact of a policy of adjuvant chemotherapy for a high risk stage I malignant teratoma on overall relapse rate of stage I patients. J Urol 148: 1453-1456
53. Oliver RTD, Ong J, Ostrowski J, Williams M (1993) One versus two courses of adjuvant therapy compared to radiotherapy of surveillance for stage I germ cell tumours. In: Jones WG, Harden P, Appleyard I (eds) Germ cell tumours III. Elsevier, Oxford New York Tokyo, pp 203-205
54. Peckham MJ, Barrett A, Husband JE, Hendry WF (1981) Orchiectomy alone in testicular stage I nonseminomatous germ cell tumors. Lancet 2: 678
55. Peng H-Q, Hogg D, Malkin D, Bailey D, Gallie BL, Bulbue M, Jewett M, Buchanan J, Goss PE (1993) Mutations of the p53 gene do not occur in testis cancer. Cancer Res 53: 3574-3578
56. Pietsch T, Serth J, Stanulla M, Kuczyk MA, Bokemeyer C, Thon WF, Jonas U (1994) Coexpression of stem cell factor and ist receptor c-kit in germ cell tumors. J Urol 151: 408 A
57. Pizzocaro G, Monfardini S (1984) No adjuvant chemotherapy in selected patients with pathologic stage II nonseminomatous germ cell tumors in the testis. J Urol 131: 677-680
58. Pizzocaro G (1985) Unilateral lymphadenectomy in preoperative clinically negative non-seminoma. In: Khoury S, Küss R, Murphy GP, Chatelain C, Karr JP (eds) Testicular cancer. Liss, New York, pp 563
59. Pizzocaro G (1991) Management of stage I nonseminoma: rationale for lymphadenectomy. In: Horwich A (ed) Testicu- lar cancer, 1st edn. Chapman & Hall. London New York Tokyo, pp 167-173
60. Pizzocaro G, Durand JC, Fuchs WA et al (1981) Staging and surgery in testicular cancer. Eur Urol 7: 1-10
61. Pont J, Höltl W, Kosak D (1990) Risk-adapted treatment choice in stage I non-seminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial. J Clin Oncol 8: 16-20
62. Read G, Stenning SP, Cullen MH et al (1991) Prospective study of surveillance for stage I testicular non seminomatous germ cell tumours (NSGCT): a study be the Medical Research Council (MRC). Proc Am Soc Clin Oncol, p 523 A
63. Richie JP (1988) Modified retroperitoneal lymphadenectomy for patients with clinical stage I testicular cancer. Semin Urol 6: 216-222
64. Richie JP (1990) Clinical stage I testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol 144: 1160-1163
65. Rodriguez E, Mathew S, Reuter V et al (1992) Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. Cancer Res 52: 2285-2291
66. Rowland RG, Donohue JP (1988) Testicular cancer: innovations in diagnosis and treatment. Semin Urol 6: 223-232
67. Samaniego F, Rodriguez E, Houldsworth J et al (1990) Cytogenetic and molecular analysis of human male germ cell tumors: chromosome 12 abnormalities and gene amplification. Genes Chromosomes Cancer 1: 289-292
68. Sago AL, Ball TP, Novicki DE (1979) Complications of retroperitoneal tymphadenectomy. Urology 13: 241-243
69. Sandemann TF, Yang C (1988) Results of adjuvant chemotherapy for low-stage nonseminomatous germ cell tumors of the testis with vascular invasion. Cancer 62: 1471-1475
70. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE (1993) Nuclear overexpression of p 53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85: 53-59
71. Schmoll HJ, Waegener W (1984) Adjuvant therapy in resectable stage II bonseminomatous testicular cancer. In: Jones SE, Salmon SE (eds): adjuvant therapy of cancer IV. Grune & Stratton, Orlando, pp 539-548
72. Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK, Jonas U (1995) p 53 immunohistochemistry as an independent prognostic factor for transitional cell carcinoma of the bladder. Br J Cancer 71: 201-205
73. Sesterhenn IA, Weiss RB, Mostofi FK, Stablein DM, Rowland RG, Falkson G, Rivkind SE, Vogelzang NJ (1992) Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J Clin Oncol 10: 69-78
74. Skinner DG, Melamud A, Lieskovsky G (1982) Complications of thoraco-abdominal retroperitoneal lymph node dissection. J Urol 127: 1107-1110
75. Sogani PC, Whitmore WF, Herr HW (1984) Orchiectomy alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis. J Clin Oncol 2: 267-270
76. Stauffenberg A, Brensing K-A (1990) Veränderungen des Hormonhaushalts durch Chemotherapie. In: Jäger N, Hartlapp JH (Hrsg) Aktueller Stand der Diagnostik und Therapie von Hodentumoren. Beitr. Onkol., Bd 40. Karger, Basel, S 115-123
77. Stephenson RA (1991) Surveillance for clinical stage I nonseminomatous testis carcinoma: rationale and results. Urol Int 46: 290-293
78. Strohmeyer T, Peter S, Hartmann M, Munemitsu S, Ackermann R, Ullrich A, Slamon DJ (1991) Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res 51: 1811-1816
79. Strohmeyer T, Reese D, Press M, Ackermann R, Hartmann M, Slamon D (1995) Expression of c-kit proto-oncogene and ist ligand stem cell factor (SCF) in normal and malignant human testicular tissue. J Urol 153: 511-515
80. Strohmeyer TG, Fleischhacker M, Imai Y, Slamon DJ, Koeffler HP (1993) Status of the p 53 tumor suppressor gene and the MDM-2 gene in human testicular tumors. J Urol 149: 311 A
81. Studer UE, Fey MF, Calderoni A, Kraft R, Mazzuchelli L, Sonntag RW (1993) Adjuvant chemotherapy after orchiectomy in high risk patients with clinical stage I nonseminomatous testicular cancer. Eur Urol 23: 444-449
82. Swanson DA, Johnson DE (1989) M. D. Anderson experience with surveillance for clinical stage I disease. In: Johnson DE, Logothetis CJ, Von Eschenbach AC (eds) Systemic therapy for genitourinary cancers. Year Book Medical Publishers. Chicago, pp 304-311
83. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS (1992) Accumulation of p 53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84: 845-854
84. Visakorpi T, Kallioniemi Op, Heikkinen A, Koivula T, Isola J (1992) Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p 53 accumulation. J Natl Cancer Inst 84: 883-887
85. Weise WH, Maleika F (1987) Penetrations- und Fertilisationstests in vivo und in vitro. In: Ludwig G, Frick J (eds) Praxis der Spermatologie, Springer, Berlin Heidelberg New York, pp 129-147
86. Weißbach L, Bode HU (1982) Die modifizierte Lymphadenektomie zur Protektion der Ejakulation. In: Illiger HJ, Sack H, Seeber S, Weißbach L (Hrsg) Nicht seminomatöse Hodentumoren. Beitr. Onkol 8. Karger. Basel, S 133-138
87. Weißbach L, Boedefeld EA for the Testicular Tumor Study Group (1987) Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol 138: 77-82
88. Weißbach L, Boedefeld EA, Horstmann-Dubral B (1990) Surgical treatment of metastatic stage II nonseminomatous testis tumor. J Urol 146: 1295-1298 S
89. Weißbach L, Bussar-Maatz R: "Wait and See"-Strategie versus Lymphadenektomie im klinischen Stadium I nichtseminomatöser Hodentumoren. In: Schmoll H-J, Weißbach L (Hrsg) Diagnostik und Therapie von Hodentumoren. Springer, Berlin Heidelberg New York, pp 161-168
90. Weißbach L, Bussar-Maatz R (1995) Können Risikofaktoren die Strategien im Stadium I des Nicht-Seminoms bestimmen? Akt Urol 26: 79-88
91. Weißbach L, Sommerhoff C, Struth B (1980) Aussagen zur Fertilität bei Patienten mit germinalen Hodentumoren. Extr Urol 3: 159-174
92. Whitmore W (1979) Surgical treatment of adult germinal testis tumor. Semin Oncol 6: 55-68
93. Williams SD, Stablein DM, Einhorn LH et al (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317: 1433-1438
94. Wishnow KI, Dunphy CH, Johnson DE, Ayala AG, Swanson DA, Ro JY, Tenney DM, Eschenbach AC, Babaian RJ (1989) Identifying patients with low risk clinical stage I nonseminomatous testicular tumors who should be treated by surveillance. Urology 34: 339-343